Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 11/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629853 | 0.73 | HTT (0.50) | KMT2ASMN1; SMN2MEN1MAPTPPARG | |
| SCHEMBL14577156 | 0.69 | CCR1 (0.44) | KMT2ASMN1; SMN2MEN1MAPTPPARG | |
| SCHEMBL631738 | 0.68 | S100A4 (0.33) | — | |
| SCHEMBL6628026 | 0.65 | LMNA (0.52) | KMT2ASMN1; SMN2MEN1MAPTCTSB | |
| SCHEMBL6623681 | 0.65 | RAB9A (0.47) | KMT2ASMN1; SMN2MEN1MAPTPPARG | |
| SCHEMBL10786966 | 0.64 | RAB9A (0.44) | KMT2ASMN1; SMN2MEN1MAPTRAB9A | |
| SCHEMBL16653954 | 0.64 | POLB (0.32) | SMN1; SMN2PPARGNPSR1ALDH1A1HPGD | |
| SCHEMBL3715462 | 0.64 | HPGD (0.45) | KMT2ASMN1; SMN2MEN1MAPTPPARG | |
| SCHEMBL562753 | 0.63 | KDM4E (0.43) | KMT2ASMN1; SMN2MAPTRAB9ANPC1 | |
| SCHEMBL10446539 | 0.63 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9425413-B2 | Conjugated side-strapped phthalocyanines and methods for producing and using the same | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150280143-A1 | Conjugated Side-Strapped Phthalocyanines and Methods For Producing and Using The Same | UNITED STATES DEPARTMENT OF ENERGY | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150280143-A1 | Conjugated Side-Strapped Phthalocyanines and Methods For Producing and Using The Same | STRA6, INCENP, LCP1 | KMT2A 1319/4885SMN1; SMN2 119/4885MEN1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.